Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
147.18
-0.87 (-0.59%)
At close: Nov 11, 2026, 4:00 PM EST
147.41
+0.23 (0.16%)
After-hours: Nov 11, 2026, 7:59 PM EST
Merck & Co. Revenue
Merck & Co. had revenue of $18.09B in the quarter ending September 30, 2026, with 4.68% growth. This brings the company's total for the last twelve months to $67.38B, up 4.89% year-over-year. In the year 2025, Merck & Co. had annual revenue of $65.01B with 1.31% growth. That makes Merck & Co. the 180th largest company in the world by revenue and 72nd in the United States.
Revenue (ttm)
$67.38B
Revenue Growth
+4.89%
P/S Ratio
5.39
Revenue / Employee
$898,373
Employees
75,000
Market Cap
362.83B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Merck & Co. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.01B | 843.00M | 1.31% |
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | -5.32B | -11.36% |
| Dec 31, 2019 | 46.84B | 4.55B | 10.75% |
| Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
| Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
| Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
| Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
| Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
| Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
| Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
| Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
| Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
| Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
| Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
| Dec 31, 2007 | 24.20B | 13.60B | 128.41% |
| Dec 31, 2006 | 10.59B | 1.09B | 11.42% |
| Dec 31, 2005 | 9.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Eli Lilly and Company | 86.46B |
| AbbVie | 66.01B |
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
MRK News
- 2 days ago - Merck reports Phase 2b MK-6024-013 trial met primary efficacy endpoint - TheFly
- 2 days ago - Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis - Business Wire
- 2 days ago - Adagene completes enrollment in muzastotug trial - TheFly
- 5 days ago - Healthcare Stocks Fall as Market Rout Spreads - WSJ
- 8 days ago - Merck gets US FDA emergency use nod for treatment of screwworm in dogs - Reuters
- 8 days ago - Merck initiates Phase 3 study of Ohtuvayre - TheFly
- 8 days ago - Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations - Business Wire
- 8 days ago - Merck downgraded to Hold from Buy at DZ Bank - TheFly